| [ Summary ] |
A total of 245 patients were diagnosed as having hepatitis B (HB)-related cirrhosis on the basis of laparoscopy and/or liver biopsies. Cumulative hepatocellular carcinogenesis rates in patients with cirrhosis were 19 % at the end of the 5th year, 30 % at the 10th year, and 36 % at the 15th year. Retrospective cohorts of patients with and without interferon therapy were observed in regard to hepatocellular carcinogenesis. Crude 5th year rates were 7 % in the interferon therapy group and 20 % in the untreated group, 10 year rates were 17 %, and 31 %, respectively. Interferon significantly decreased carcinogenesis rates in patients with HB-related cirrhosis. A propensity score was introduced to analyze the anti-carcinogenic activity of entecavir in retrospective cohorts with HB-cirrhosis. After adjusting background factors using a calculated score, hepatocellular carcinogenesis rates in patients with and without entecavir administration were, 1.2 % and 7.2 % at the end of 3rd year, and 3.7 % and 13.7 % at the 5th year, respectively. Entecavir also significantly decreased carcinogenesis rates in HB-positive patients with cirrhosis. |